Piper Jaffray Reiterates Overweight Rating on Novavax on Initiation of Phase I H7N9 Avian Flu Study

In a report published on Monday, Piper Jaffray analyst Edward A. Tenthoff reiterated an Overweight rating and a $3 price target on Novavax (NASDAQ: NVAX ). In the report, Piper Jaffray stated, "This morning, Novavax began enrollment of a Phase I study of its monovalent virus- like particle (VLP) vaccine